RESEARCH PROFILE
SEMAX
Synthetic ACTH-Derived Peptide • Neuroprotective & Cognitive Research
Semax is a synthetic seven-amino-acid peptide developed from a fragment of adrenocorticotropic hormone, or ACTH. Research has focused on neuroprotection, cognitive function, neurotrophic signaling, cerebral ischemia, inflammatory pathways, and nervous-system recovery.
Human clinical literature exists, particularly from Russia, but Semax has not undergone the type of large multinational clinical-development program generally associated with FDA-approved neurologic drugs.
NEUROPEPTIDE RESEARCH • HUMAN CLINICAL LITERATURE • NOT FDA APPROVED IN THE U.S.
SEMAX AT A GLANCE
Compound Type
Synthetic heptapeptide
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro
Origin
ACTH-derived peptide analog
Primary Research Focus
Neuroprotection • Cognition • Neurotrophic signaling • Cerebral ischemia
Proposed Pathways
BDNF • TrkB • Dopaminergic signaling • Serotonergic signaling • Inflammatory regulation
Human Evidence
Clinical literature exists, primarily from Russia
Regulatory Status
Not FDA approved in the United States
IMPORTANT DISTINCTION
Semax was developed from an ACTH-derived sequence, but its research focus is substantially different from the endocrine effects normally associated with full-length ACTH.
The Project source describes Semax as an ACTH(4-10)-related analog incorporating a Pro-Gly-Pro sequence intended to improve stability.
Its principal research literature concerns the central nervous system, rather than use as an ACTH replacement or conventional endocrine therapy.
WHAT IS SEMAX?
Semax is a synthetic peptide consisting of seven amino acids:
Met-Glu-His-Phe-Pro-Gly-Pro
It was developed in Russia from research involving the ACTH(4-10) fragment.
Researchers added the Pro-Gly-Pro sequence to the ACTH-derived portion to improve peptide stability while preserving proposed neuroactive properties.
WHY WAS SEMAX DEVELOPED?
Research programs involving Semax have examined its potential effects on:
Cognitive performance
Memory and attention
Cerebral ischemia
Stroke recovery
Neuroprotection
Neurotrophic signaling
Inflammatory pathways
Oxidative stress
INTRANASAL RESEARCH
Your Project source identifies intranasal administration as the most extensively studied route in the published Semax literature.
Subcutaneous administration is discussed in research and community contexts, but the Project source specifically notes that it is less represented in the human clinical literature.
That distinction matters when interpreting evidence.
Results from intranasal clinical studies should not automatically be assumed to apply to other routes.
MECHANISM OF ACTION
Semax does not have one completely established human mechanism.
Research suggests that it may influence several nervous-system signaling pathways simultaneously.
BDNF & NEUROTROPHIC SIGNALING
One of the most frequently discussed mechanisms involves brain-derived neurotrophic factor, or BDNF.
Preclinical research cited in your Project profile reports changes in:
BDNF expression
TrkB signaling
Neurotrophin-related gene activity
BDNF participates in neuronal survival, synaptic plasticity, learning, and memory.
DOPAMINERGIC SIGNALING
Preclinical studies have examined Semax's effects on dopamine-related signaling.
Research suggests modulation of dopaminergic pathways rather than the simple direct stimulation produced by conventional stimulant drugs.
SEROTONERGIC SIGNALING
Semax has also been studied for potential effects on serotonin-related signaling.
The clinical significance of these findings remains incompletely established.
MELANOCORTIN-RELATED BIOLOGY
Because Semax originated from an ACTH-derived sequence, researchers have examined interactions with melanocortin-related biological pathways.
However, Semax should not be described as producing the full hormonal effects of ACTH.
INFLAMMATORY SIGNALING
Experimental research has reported changes in inflammatory mediators following Semax exposure.
This has contributed to interest in the peptide in models of ischemic brain injury and nervous-system stress.
OXIDATIVE STRESS & NEUROPROTECTION
Preclinical research has also explored effects on oxidative stress and cellular injury.
These mechanisms are among the proposed explanations for findings in ischemia and neuroprotection models.
IMPORTANT MECHANISM LIMITATION
Changes in BDNF, neurotransmitter signaling, inflammatory markers, or gene expression do not establish that Semax improves cognition or treats neurologic disease in healthy humans.
Mechanistic findings and clinical outcomes should remain separate.
WHAT THE RESEARCH SHOWS
HUMAN CLINICAL LITERATURE
Unlike many experimental peptides, Semax has published human clinical literature.
However, your Project profile emphasizes that much of this evidence originates from Russian-language clinical research and regional medical literature.
The evidence therefore warrants more nuance than either calling Semax “unproven” or treating it as equivalent to a widely approved neurologic medication.
ISCHEMIC STROKE RESEARCH
Human clinical research cited in the Project profile has examined Semax in patients with acute ischemic stroke.
Reported areas of investigation have included:
Neurologic recovery
Functional outcomes
Inflammatory signaling
Neurotrophic markers
Some studies reported favorable neurologic or recovery-related findings.
However, the literature does not constitute a large multinational regulatory evidence program.
COGNITIVE & ATTENTION RESEARCH
Semax has also been investigated in cognitive and neuropsychological contexts.
Reported research areas include:
Attention
Memory
Learning
Cognitive performance under stress
Some studies report favorable effects, but the overall human evidence base remains limited compared with established cognitive or neurologic therapies.
BDNF & GENE-EXPRESSION RESEARCH
Experimental studies cited in your Project source have reported changes in:
BDNF-related pathways
TrkB signaling
Gene expression
Neuroplasticity-associated signaling
These findings provide mechanistic support for continued investigation.
CEREBRAL ISCHEMIA
Animal and cellular models have investigated Semax in ischemic brain injury.
Reported findings include changes involving:
Inflammatory signaling
Oxidative stress
Neuronal injury
Neurotrophic pathways
These findings remain preclinical unless supported by corresponding human outcomes.
ANXIETY & BEHAVIORAL RESEARCH
The Project profile also identifies preclinical research examining behavioral and anxiety-related effects.
These findings should not be interpreted as evidence that Semax is an established treatment for anxiety disorders.
IMPORTANT EVIDENCE LIMITATIONS
Semax has more human research than many experimental peptides, but important limitations remain.
The literature is characterized by:
A large proportion of Russian-language publications
Relatively small clinical studies
Limited independent international replication
Variation in study design and endpoints
Predominantly intranasal clinical research
Limited evidence for subcutaneous administration
No U.S. FDA approval
Semax should therefore not be represented as a clinically established cognitive enhancer, stroke treatment, antidepressant, or neuroprotective therapy in the United States.
SAFETY & RESEARCH CONSIDERATIONS
The Project source describes Semax as generally well tolerated in the available literature, but the human safety database is considerably smaller than that of an FDA-approved neurologic medication.
REPORTED EFFECTS
Your Project profile identifies reported effects including:
Nasal irritation with intranasal administration
Headache
Temporary fatigue
Dizziness
Restlessness
Anxiety or overstimulation
Sleep disturbance
Individual response may vary.
INTRANASAL ADMINISTRATION
Because intranasal Semax represents much of the human literature, local nasal effects are particularly relevant.
Reported concerns include:
Nasal irritation
Dryness
Sneezing
Local discomfort
STIMULATION & SLEEP
Some users report an activating or stimulating effect.
Your Project source therefore identifies possible:
Restlessness
Anxiety
Insomnia
Sleep disruption
as considerations, particularly with administration later in the day.
NEUROLOGIC & PSYCHIATRIC CONDITIONS
The Project profile recommends additional caution in people with significant neurologic or psychiatric histories.
Changes in:
Mood
Anxiety
Sleep
Agitation
Neurologic symptoms
warrant appropriate medical evaluation.
MEDICATION INTERACTIONS
Robust human interaction studies are limited.
Your Project source identifies particular caution around medications affecting:
Dopamine
Serotonin
Central nervous system stimulation
Blood pressure
The absence of a documented interaction does not establish safety.
PREGNANCY & BREASTFEEDING
Adequate safety data are not established.
LONG-TERM SAFETY
Long-duration controlled human safety data remain limited, particularly for repeated use outside the intranasal clinical contexts represented in the literature.
REGULATORY CONTEXT
SEMAX IS NOT FDA APPROVED
Semax is not an FDA-approved drug for any indication in the United States.
Your Project source specifically distinguishes U.S. status from its regulatory history in other countries.
UNITED STATES
Semax has no FDA-approved prescription drug product.
It should not be represented as an FDA-approved treatment for:
Stroke
Cognitive impairment
ADHD
Anxiety
Depression
Brain injury
Neurodegenerative disease
FDA COMPOUNDING HISTORY
Your Project source documents an important regulatory change.
Semax had previously appeared on FDA's 503A Category 2 list of bulk drug substances raising potential significant safety concerns.
The Project profile states that Semax was removed from Category 2 on April 23, 2026 after its nomination was withdrawn.
Removal from that list should not be interpreted as FDA approval or a determination that Semax is safe or effective.
PHARMACY COMPOUNDING ADVISORY COMMITTEE
The Project source also identifies FDA Pharmacy Compounding Advisory Committee consideration scheduled for July 23–24, 2026 concerning Semax-related compounding questions.
Again, regulatory review does not constitute therapeutic approval.
RUSSIA
Your Project source describes Semax as having a substantially different regulatory history in Russia, where it has been used in clinical contexts involving neurologic conditions.
That regional history does not confer U.S. approval.
INTERNATIONAL STATUS
Regulatory treatment varies by jurisdiction.
IMPORTANT REGULATORY DISTINCTION
Approved or registered elsewhere ≠ FDA approved
Removal from an FDA Category 2 list ≠ FDA approval
Published clinical research ≠ regulatory approval
Research-use availability ≠ established medical treatment
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
SEMAX 10 MG
Laboratory
Optiq Health Labs
Sample Name
Semax 10mg
Lot
kizen72826
Sample ID
1263.OPT.260910
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Report Date
September 18, 2026
Reported Net Content
9.65 mg/vial
Reported Purity
99.3%
Identity
LC-MS Confirmation • Semax Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Dolotov OV, Karpenko EA, Inozemtseva LS, et al.
Research examining Semax, an ACTH(4-10) analog, and cognitive effects with regulation of BDNF and TrkB expression in the rat hippocampus.
Brain Research. 2006.
Preclinical neurotrophic and cognitive research.
Eremin KO, Kudrin VS, Saransaari P, et al.
Research examining Semax and dopaminergic and serotonergic brain systems in rodents.
Neurochemical Research. 2005.
Preclinical neurotransmitter research.
Berlina IV, et al.
Research examining Semax and inflammatory nervous-system signaling.
Experimental neuroinflammatory research.
Kost NV, Sokolov OY, Gabaeva MV, et al.
Research examining Semax and enkephalin-degrading enzymes.
Mechanistic peptide research.
Medvedeva EV, Dmitrieva VG, Povarova OV, et al.
Research examining Semax and gene expression associated with immune and vascular systems in focal cerebral ischemia.
Preclinical ischemia and gene-expression research.
Filippenkov IB, Stavchansky VV, Glazova NY, et al.
Research examining protective properties of ACTH-derived peptide fragments during experimental cerebral ischemia.
Preclinical neuroprotection research.
Ismailova LS, Kopylova IA, Akatova OV, et al.
Research examining antidepressant and anti-stress effects of Semax-related ACTH fragments in animal models.
Preclinical behavioral research.
Gusev EI, Skvortsova VI, Martynov MY, et al.
Clinical research examining Semax during acute cerebral ischemia.
Human stroke-related research.
Ashmarin IP, et al.
Research and development literature concerning Semax and peptide bioregulation.
U.S. Food and Drug Administration
Regulatory information concerning bulk drug substances used in compounding and Semax-related review.
EVIDENCE NOTE
Semax occupies an unusual position among research peptides because published human clinical literature exists, particularly in Russia.
However, much of the evidence originates from a relatively concentrated research tradition, with limited large-scale independent international replication.
The evidence therefore supports describing Semax as a human-studied investigational neuropeptide, but not as an established FDA-approved cognitive or neurologic therapy.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish Semax as safe or effective for personal use.
Semax is a synthetic ACTH-derived heptapeptide studied in relation to neuroprotection, cognition, neurotrophic signaling, cerebral ischemia, inflammatory pathways, and nervous-system function.
Human clinical literature exists, particularly from Russia, but the evidence base is substantially smaller and less internationally replicated than that supporting established FDA-approved neurologic therapies.
Semax is not FDA approved for any therapeutic indication in the United States.
Findings from animal studies, cellular research, Russian clinical literature, or intranasal studies should not automatically be generalized to other populations, indications, formulations, or routes of administration.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.